SEC Form 4/A · accession 0001104659-18-043872

LIGAND PHARMACEUTICALS INC · LGND

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.

Reporting owner

Stephen L Sabba

Director

Period of report

Jun 19, 2018

Accepted (ET)

Jul 3, 2018 · 5:05 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000886163

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jun 19, 2018	A	493	$0.00	A	26,856	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F2	$195.91	Jun 19, 2018	A	2,474	A	—	Jun 19, 2028	Common Stock	2,474	2,474	D
Non-Qualified Stock Option (right to buy)^F3	$113.50	holding	—	—	—	—	May 25, 2027	Common Stock	2,456	2,456	D

Explanation of responses

F1These securities, as represented in Column 5, include a grant of 493 restricted shares approved by the Board of Directors of the Company at the 2018 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date.
F2These securities, as represented in Column 5, were acquired by a grant of 2,474 shares approved by the Board of Directors of the Company at the 2018 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time.
F3These securities were previously reported on a Form 4 for this Reporting Person filed on May 30, 2017, and are included on this Form 4 only to report that they are currently fully vested and exercisable.

Remarks

This amendment is being filed to correct the exercise price listed in item 2 of Table II in order to reflect the market closing price on the grant date.